September 2024 – December 2024 | DemDx Clinical Release Notes – updates based on NICE guidance updates
All new NICE Guidance in the last quarter has been reviewed by the DemDx Clinical Governance committee to ensure our clinical content remains up to date and complies with national best practice. The following topics were deemed to be relevant to primary care and changes have been made to align DemDx platform content with the latest clinical guidance:
Recurrent UTI Management
• The option of vaginal oestrogen for managing menopausal women with recurrent UTIs.
• The option of methenamine hippurate as an alternative to daily antibiotic prophylaxis for women with recurrent UTIs.
Asthma Diagnosis & Management
• New recommendations on objective tests for diagnosing asthma in adults and children.
• New guidance on monitoring asthma control and the importance of self-management plans.
• New guidance on the treatment of asthma in children and adults, including MART therapy in older children and adults.
• Importance of making patients/carers aware of the rare but potential neuropsychiatric side effects when prescribing montelukast.
Menopause: Identification & Management (NG23, Dec 2024 Update)
• The need to advise patients of the importance of maintaining muscle mass and strength through physical activity.
• To consider offering cognitive behavioral therapy (CBT) as a management option.
• To consider offering vaginal oestrogen for those with genitourinary symptoms.
• To use the NICE discussion aid on HRT risks/benefits when discussing treatment options.
Functional Neurological Disorder (FND)
• New differential created and populated in line with NICE guidance. Differential added to relevant pathways in DemDx.
Latest articles
Managing Risks in Pharmacy Based Consultations
September 3, 2025
DemDx and Bromley by Bow Health partnership
August 8, 2023